硬脂酸阿霉素纳米粒的制备及在抗肝癌中的应用  

Preparation and anti-hepatocarcinoma effect of stearic acid-doxorubicin nanoparticles

作　　者：陈汝福[1] 王捷[1] 李志花[1] 陈积圣[1] 

机构地区：[1]中山大学附属第二医院肝胆外科,广州市510120

出　　处：《中华肝胆外科杂志》2005年第2期125-127,共3页Chinese Journal of Hepatobiliary Surgery

基　　金：广东省医学科学研究基金(A2002201);广东省自然科学基金(2003A031700)

摘　　要：目的　合成硬脂酸聚乙二醇阿霉素纳米微粒(doxorubicin solid lipid nanoparticles polyethylene glycol, DOX SLNs PEG)并检测其相关参数,观察其对人肝癌细胞杀伤作用。方法　以“乳化蒸发 低温固化”法合成 DOX SLNs PEG 纳米粒,透射电镜计算粒径,分光光度法计算载药率,MTT法观察对肝癌细胞的体外杀伤作用。结果　DOX SLNs PEG 纳米粒平均粒径( 120±4 84) mm,包封率68 6%,体外释放实验提示,7 d可释放所载60%左右的药物;体内抑瘤实验表明:控释制剂间隔给药疗效已优于未包载药物每日给药的疗效,量效关系明显。结论　DOX SLNs PEG纳米粒可有效抑制肝癌细胞的生长。Objective To prepare DOX SLNs PEG nanoparticles, detect their correlative parameters and explore their anti hepatocarcinoma effect in human being. Methods The DOX SLNs PEG nanoparticles were prepared by the method of 'emulsion evaporation solidification at low temperature'. The diameter of the nanoparticles was determined by transmission electron microphotography. The drug carrying amount of DOX SLNs PEG nanoparticles was calculated by spectrophotometer. The inhibitory effect of the particles on hepatocarcinoma cell growth was determined by MTT assay in vitro. Results The mean diameter of DOX SLNs PEG nanoparticles was 120±4 84 mm, the drug carrying amount of the particles was 95%. In vitro tests manifested that DOX SLNs PEG nanoparticles discharged nearly 60% of the drugs in 7 days. The in vivo experiment indicated that the efficacy of control releasing agent by interval drug delivery had advantages over one of the unenveloped drug by per diem drug delivery. It showed apparent dosage efficacy relationship. Conclusions DOX SLNs PEG nanoparticles can effectively inhibit the growth of hepatocarcinoma cells.

关 键 词：SLN 纳米粒 阿霉素 载药 肝癌细胞 观察 药物 PEG 间隔 生长 

分 类 号：TQ463[化学工程—制药化工] R735.7[医药卫生—肿瘤]